The phase 3 SONIA trial showed deferring CDK4/6 inhibitor treatment may not compromise HRQOL in patients with HR-positive/HER2-negative advanced breast cancer.
Olaparib improved invasive disease-free survival, distant disease-free survival, and overall survival in high-risk ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback